Effect and Safety of Semaglutide 2.4 mg Once-weekly in Subjects With Overweight or Obesity and Type 2 Diabetes
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 21 Jan 2019
At a glance
- Drugs Semaglutide (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms STEP 2
- Sponsors Novo Nordisk
- 04 Jan 2019 Status changed from recruiting to active, no longer recruiting.
- 08 Aug 2018 According to a Novo Nordisk media release, all four STEP trials are expected to be completed in 2020.
- 19 Jun 2018 Status changed from not yet recruiting to recruiting.